Elotuzumab specifications and parameters

Elotuzumab (Elotuzumab) is a humanized IgG1 monoclonal antibody targeting the SLAMF7 receptor. When it was launched internationally, its specifications were mainly set around the clinical needs of intravenous infusion. Common overseas specifications are mostly provided in the form of single-dose vials to meet flexible ratios during combined administration. At this stage, the main specifications are concentrated in two dosage forms: 300mg and 400mg, of which 300mg is more widely used and is commonly found in fixed doses or dose combinations calculated based on body weight.

The drug is packaged in the form of freeze-dried powder, which needs to be dissolved and diluted before use, and then the dose is calculated according to body weight for intravenous infusion. Different specifications do not affect the effectiveness of the drug itself, but are designed to adapt to the dosage requirements of different body types and different courses of treatment, so that clinical doses can be adjusted to avoid drug waste. Since evolizumab is a monoclonal antibody, cold chain and professional operating procedures must be strictly followed during storage, transportation and use.

The core principle of specification design is to match its dosing frequency and treatment cycle. Evolizumab is mostly used in combination regimens clinically, so the dosage is generally determined by multiple drugs. Drug specifications must ensure accurate calculation of infusion concentrations in multi-drug combinations and facilitate dispensing by hospital pharmacies. Therefore, many countries adopt similar bottle specifications to maintain consistency. After dissolution, the medicinal solution must be used within the specified time to avoid a decrease in activity due to exceeding the stability period.

Although it has not yet been launched in China, overseas packaging parameters have been widely cited and have become an important basis for medical institutions to formulate usage procedures. Each vial comes with a batch number, production date and expiry date, ensuring that high standards of quality control are maintained in the use of therapeutic antibodies. The standardization of specifications will also help in quality comparison of future biosimilars after they enter the market, so currently available versions basically adopt a highly unified design.

Reference materials:https://www.empliciti.com/